Oxford Biomedica FY revenues grow, one‑off gain props up earnings

(Sharecast News) - Contract development and manufacturing firm Oxford Biomedica said on Tuesday that it expects to report a strong rise in full year revenues, but signalled that underlying profitability would only be modest despite a one‑off boost from its US acquisition. Oxford Biomedica expects FY25 revenues to increase by around 30% to between £166m and £169m, or £168m to £171m at constant currency, placing the outcome at the upper end of guidance and well ahead of the £128.8m reported for FY24.

Operating EBITDA for the year was forecast to come in at a mid‑to‑high single‑digit million‑pound profit at constant currency, helped by a larger‑than‑expected non‑recurring gain linked to its recent Durham, North Carolina acquisition.

However, excluding that one‑off item, underlying operating EBITDA is expected to be only a low single‑digit million‑pound profit - a sharp improvement on FY24's £15.3m loss, but still thinner than analysts had hoped.

Oxford Biomedica also reported a 20% increase in contracted client order value for 2025, rising to £224m from £186m, reflecting stronger demand from both existing and new customers.

Despite the revenue momentum and order growth, the heavier‑than‑expected reliance on a non‑recurring gain to achieve profitability will likely weigh on sentiment.

As of 0810 GMT, Oxford Biomedica shares were down 4.69% at 737.67p.











Reporting by Iain Gilbert at Sharecast.com